Kivizidiale

Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. They are prescribed to lower intraocular pressure in patients with open‑angle glaucoma and ocular hypertension.\n\nGNH India supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is used in the management of glaucoma and related ocular pressure disorders.\n\nOpen‑angle glaucoma: reduces intraocular pressure to prevent optic nerve damage.\nOcular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma.\nSecondary glaucoma (adjunctive therapy): assists in controlling pressure when monotherapy is insufficient.

Kivizidiale may cause ocular and systemic adverse reactions.\n\nCommon Side Effects:\n- Eye irritation or burning sensation\n- Blurred vision\n- Redness of the eye\n- Dry eye or foreign‑body sensation\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (e.g., angio‑edema)\n- Exacerbation of asthma or chronic obstructive pulmonary disease\n- Cardiac arrhythmia or bradycardia\n- Sudden loss of vision\n- Deep ocular pain

Before prescribing Kivizidiale, consider the following precautions.\n\nMonitor intraocular pressure: adjust therapy based on pressure readings.\nAssess respiratory status: avoid in patients with active asthma or severe COPD.\nEvaluate cardiac function: caution in bradycardia, heart block, or heart failure.\nAvoid concurrent ocular beta‑blocker use: risk of additive systemic effects.\nStore at room temperature: keep in the original container, protect from light and moisture.

Kivizidiale can interact with other medications; awareness of interaction severity is important.\n\nMajor Interactions (Avoid):\n- Systemic non‑selective beta‑blockers (e.g., propranolol): may cause additive bradycardia or hypotension.\n- Other ocular beta‑blocker preparations: increase risk of systemic beta‑blockade.\n- Systemic carbonic anhydrase inhibitors: may enhance intraocular pressure‑lowering effect leading to over‑reduction.\n\nModerate Interactions (Monitor Closely):\n- Topical corticosteroids: may increase intraocular pressure when used together.\n- Anticholinergic eye drops: potential for reduced efficacy of timolol.